MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-aα

Molecular Cancer

Volumn 15, Issue 1, 2016, Pages

  Chen, Shuo ^a   Sun, Kai Xuan ^a   Liu, Bo Liang ^a   Zong, Zhi Hong ^a   Zhao, Yang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Endometrial carcinoma; MiR 505; Progression; TGF a ; Tumorigenesis

Indexed keywords

CYCLIN DEPENDENT KINASE 2; GELATINASE A; GELATINASE B; MICRORNA; MICRORNA 505; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; MIRN505 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RNA BINDING; TGFA GENE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG SCREENING; ENDOMETRIUM TUMOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; METASTASIS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOMETRIAL NEOPLASMS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICE, INBRED BALB C; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TRANSFECTION; TRANSFORMING GROWTH FACTOR ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956724800     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-016-0496-4     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Deligdich L, Holika CF. Endometrial carcinoma: two diseases? Cancer Detect Prev. 1987;10(3-4):237-46.
3. Deligdisch L. When cancer of the endometrium is not a good cancer. Rev Fr Gynecol Obstet. 1990;85(10):513-6.
4. Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I, Shalev E. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagn Pathol. 2014;9:77.
5. Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol. 2009;36(2):145-54.
6. Lotocki RJ, Copeland LJ, DePetrillo AD, Muirhead W. Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am J Obstet Gynecol. 1983;146:141-5.
7. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008;110(2):206-15.
8. Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, et al. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol. 2014;132(1):70-5.
9. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):347-55.
10. Olivieri F, Rippo MR, Monsurrò V, Salvioli S, Capri M, Procopio AD, et al. MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res Rev. 2013;12(4):1056-68.
11. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6-7.
12. Bray F, Loos AH, Oostindier M, Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer. 2005;117:123-31.
13. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495-500.
14. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787-98.
15. Yan J, Gumireddy K, Li A, Huang Q. Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer. Curr Cancer Drug Targets. 2013;13(9):930-4.
16. Zhong X, Coukos G, Zhang L. miRNAs in human cancer. Methods Mol Biol. 2012;822:295-306.
17. Vasudevan S, Tong Y, Steitz JA. Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation. Science. 2007;318(5858):1931-4.
18. Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer. 2011;10:135.
19. Verduci L, Simili M, Rizzo M, Mercatanti A, Evangelista M, Mariani L, et al. MicroRNA (miRNA)-mediated interaction between leukemia/lymphoma-related factor (LRF) and alternative splicing factor/splicing factor 2 (ASF/SF2) affects mouse embryonic fibroblast senescence and apoptosis. J Biol Chem. 2010;285:39551-63.
20. Zhu M, Yi M, Kim CH, Deng C, Li Y, Medina D, et al. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol. 2011;12(8):R77.
21. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-69.
22. Qin Z, He W, Tang J, Ye Q, Dang W, Lu Y, et al. MicroRNAs Provide Feedback Regulation of Epithelial-Mesenchymal Transition Induced by Growth Factors. J Cell Physiol. 2015; May 29.
23. Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP, et al. Validation of Expression Patterns for Nine miRNAs in 204 Lymph-Node Negative Breast Cancers. PLoS One. 2012;7(11), e48692.
24. Badawy AA, El-Hindawi A, Hammam O, Moussa M, Gabal S, Said N. Impact of epidermal growth factor receptor and transforming growth factor-aα on hepatitis C virus-induced hepatocarcinogenesis. APMIS. 2015;123(10):823-31.
25. Giricz O, Calvo V, Peterson EA. TACE-dependent TGF-alpha shedding drives triple-negative breast cancer cell invasion. Int J Cancer. 2013;133(11):2587-95.
26. DeHaan AM, Wolters NM, Keller ET and Ignatoski KM. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate. 2009; 69:528-37.
27. Ferrer I, Alcántara S, Ballabriga J, Olivé M, Blanco R, Rivera R, et al. Transforming growth factor-aα (TGF-aα) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Prog Neurobiol. 1996;49(2):99-123.
28. Schreiber AB, Winkler ME, Derynck R. Transforming growth factoralpha:a more potent angiogenic mediator than epidermal growth factor. Science. 1986;232:1250-3.
29. Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. miR-152 controls migration and invasive potential by targeting TGFaα in prostate cancer cell lines. Prostate. 2013;73(10):1082-9.
30. Jin Y, Peng D, Shen Y, Xu M, Liang Y, Xiao B, et al. MicroRNA-376c inhibits cell proliferation and invasion in osteosarcoma by targeting to transforming growth factor-alpha. DNA Cell Biol. 2013;32(6):302-9.
31. Qin W, Pan Y, Zheng X, Li D, Bu J, Xu C, et al. MicroRNA-124 regulates TGF-aα-induced epithelial-mesenchymal transition in human prostate cancer cells. Int J Oncol. 2014;45(3):1225-31.
32. Hou CH, Lin FL, Tong KB, Hou SM, Liu JF. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol. 2014;89(4):453-63.
33. Kimura M, Moteki H, Ogihara M. Involvement of endogenous transforming growth factor-aα in signal transduction pathway for interleukin-1β-induced hepatocyte proliferation. Eur J Pharmacol. 2014;745:223-33.
34. Mouradian M, Kikawa KD, Johnson ED, Beck KL, Pardini RS. Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth. Prostaglandins Leukot Essent Fatty Acids. 2014;90(4):105-15.
35. Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, et al. Increased TGF-a as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clin Cancer Res. 2013;19(24):6751-65.
36. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol. 2010;28:1181-9.
37. Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo. 1994;8(1):113-23.
38. Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, et al. A four-marker signature of TNF-RII, TGF-aα, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014;12:19.
39. McInnes C, Wang J, Al Moustafa AE, Yansouni C, O'Connor-McCourt M, Sykes BD. Structure-based minimization of transforming growth factor-alpha (TGF-alpha) through NMR analysis of the receptor-bound ligand. Design, solution structure, and activity of TGF-alpha 8-50. J Biol Chem. 1998;273(42):27357-63.
40. Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 2003;4(6):216.
41. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699-711.
42. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006;3(12), e486.
43. Volkmann N, Marassi FM, Newmeyer DD, Hanein D. The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ. 2014;21(2):206-15.
44. Jeggo PA. DNA repair: PARP - another guardian angel? Curr Biol. 1998;8(2):R49-51.
45. Donizy P, Halon A, Surowiak P, Pietrzyk G, Kozyra C, Matkowski R. Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells. Eur J Histochem. 2013;57(4), e35.
46. Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther. 2015;9:5225-35.